Genomic analysis of young people with diabetes in Indonesia
Genomic Study of Young-Onset Diabetes Mellitus
Indonesia University · NCT06273059
This study is testing the genetic factors of young people with diabetes in Indonesia to see if it can help improve their diagnosis and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 8 Years to 40 Years |
| Sex | All |
| Sponsor | Indonesia University (other) |
| Locations | 1 site (Jakarta Pusat, DKI Jakarta) |
| Trial ID | NCT06273059 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the genomic aspects of young-onset diabetes mellitus (DM) in Indonesia, particularly the subtypes such as Mature Onset Diabetes of the Young (MODY). It aims to identify and properly diagnose the spectrum of young-onset DM, which is crucial for improving treatment outcomes. The study will involve diabetic patients aged 8-40 years and healthy controls, assessing their genetic profiles to better understand the condition. The findings could lead to more effective and cost-efficient treatment options for young patients with diabetes.
Who should consider this trial
Good fit: Ideal candidates include diabetic patients aged 8-40 years who meet specific diagnostic criteria for diabetes as per Indonesian guidelines.
Not a fit: Patients experiencing severe illness or those outside the specified age range may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and treatment strategies for young patients with diabetes, potentially reducing complications and enhancing quality of life.
How similar studies have performed: While there is ongoing research in the field of diabetes genetics, this specific focus on young-onset diabetes in Indonesia is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Diabetic patients
* Diabetic patient fulfilling criteria from Indonesian Endocrinology Association (PERKENI) 2021 guidelines:
* Fasting blood glucose 126 mg/dL
* 2-hour post oral glucose blood glucose/oral glucose tolerance test 200 mg/dL
* HbA1c 6.5%
* Random blood glucose 200 mg/dL with classic symptoms or hyperglycemic crisis.
* Patients aged 8-40 years old when diagnosed with diabetes mellitus
* Registered in Dr. Cipto Mangunkusumo National General Hospital and satellite hospitals
* Willing to participate in the study with proof of informed consent agreement
Exclusion Criteria:
* Subject is experiencing severe illness
Healthy controls Inclusion criteria
* Aged 8-40 years old
* Fulfilling criteria of normal blood glucose levels according to Indonesian Endocrinology Association (PERKENI) 2021 guidelines:
* Fasting blood glucose 100 mg/dL
* 2-hour post oral glucose blood glucose/oral glucose tolerance test 140 mg/dL
* HbA1c 5.7% Exclusion criteria
* Subject is unwilling to participate in the study
Where this trial is running
Jakarta Pusat, DKI Jakarta
- Cipto Mangunkusumo Hospital — Jakarta Pusat, DKI Jakarta, Indonesia (RECRUITING)
Study contacts
- Principal investigator: Dicky Tahapary — Indonesia University
- Study coordinator: Dicky Tahapary
- Email: penelitian.endokrin@gmail.com
- Phone: +6213907703
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Genomic, Diabetes Mellitus, MODY, Diabetes mellitus